Log in

NASDAQ:VTVT - vTv Therapeutics Stock Price, Forecast & News

$2.02
-0.01 (-0.49 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$1.89
Now: $2.02
$2.08
50-Day Range
$1.63
MA: $2.65
$3.75
52-Week Range
$1.23
Now: $2.02
$4.23
Volume146,202 shs
Average Volume899,590 shs
Market Capitalization$131.83 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.8
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Read More
vTv Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Book Value($0.77) per share

Profitability

Net Income$-13,040,000.00
Net Margins-490.27%

Miscellaneous

Employees52
Market Cap$131.83 million
Next Earnings Date5/6/2020 (Estimated)
OptionableNot Optionable

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.


vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

How has vTv Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VTVT shares have decreased by 16.9% and is now trading at $2.02. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of vTv Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for vTv Therapeutics.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for vTv Therapeutics.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) issued its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. The biotechnology company earned $3.38 million during the quarter, compared to analysts' expectations of $2.06 million. View vTv Therapeutics' earnings history.

What price target have analysts set for VTVT?

2 analysts have issued 1 year target prices for vTv Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate vTv Therapeutics' stock price to reach $7.00 in the next year. This suggests a possible upside of 246.5% from the stock's current price. View analysts' price targets for vTv Therapeutics.

What are Wall Street analysts saying about vTv Therapeutics stock?

Here are some recent quotes from research analysts about vTv Therapeutics stock:
  • 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (3/24/2020)
  • 2. HC Wainwright analysts commented, "Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success." (8/16/2019)

Has vTv Therapeutics been receiving favorable news coverage?

News headlines about VTVT stock have trended negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. vTv Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near future. View the latest news aboutvTv Therapeutics.

Who are some of vTv Therapeutics' key competitors?

What other stocks do shareholders of vTv Therapeutics own?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the following people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
  • Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of America Corp DE (0.24%), Barclays PLC (0.24%) and Renaissance Technologies LLC (0.07%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View institutional ownership trends for vTv Therapeutics.

Which institutional investors are buying vTv Therapeutics stock?

VTVT stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Barclays PLC, and Renaissance Technologies LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas, and Ronald O Perelman. View insider buying and selling activity for vTv Therapeutics.

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $2.02.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $131.83 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe. View additional information about vTv Therapeutics.

What is vTv Therapeutics' official website?

The official website for vTv Therapeutics is http://www.vtvtherapeutics.com/.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  327 (Thanks for Voting!)
Underperform Votes:  303 (Thanks for Voting!)
Total Votes:  630
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel